


## CLAIMS

1. *N*-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl} amino)-1-methyl-4,5-dihydro-1*H*-pyrazolo[4,3-*h*]quinazoline-3-carboxamide phosphate of formula (II):



2. Compound according to claim 1, obtained as crystalline form I characterised by its X-ray powder diffractogram by the Bragg's angles 2 theta (expressed in terms of  $^{\circ}\pm 0.2$ ) 2.76, 8.10, 10.79, 13.49, 16.13, 17.37, 17.62, 19.77, 21.94, 24.18, 24.66.

3. Process for obtaining the compound of formula (II) according to claim 1 or 2, which process comprises reacting the starting material *N*-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl} amino)-1-methyl-4,5-dihydro-1*H*-pyrazolo[4,3-*h*]quinazoline-3-carboxamide, with 1 to 2 equivalents of a  $\text{H}_3\text{PO}_4$  solution in an organic solvent.

4. Process according to claim 3 wherein the organic solvent is EtOH.

5. Compound according to claim 1, obtained as crystalline form II characterised by its X-ray powder diffractogram by the Bragg's angles 2 theta (expressed in terms of  $^{\circ}\pm 0.2$ ) 9.43, 9.86, 12.23, 13.70, 14.81, 18.01, 19.78, 20.73, 24.55, 24.82, 26.81.

6. Process for obtaining the compound of formula (II) according to claim 1 or 5, which process comprises reacting the starting material *N*-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl} amino)-1-methyl-4,5-dihydro-1*H*-pyrazolo[4,3-*h*]quinazoline-3-carboxamide, with 1 to 2 equivalents of a H<sub>3</sub>PO<sub>4</sub> solution in water.

7. Pharmaceutical composition comprising the compound of formula (II) according to claims 1, 2 or 5 in combination with one or more pharmaceutically acceptable excipients.

8. Pharmaceutical composition according to claim 7 wherein compound of formula (II) is *N*-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl} amino)-1-methyl-4,5-dihydro-1*H*-pyrazolo[4,3-*h*]quinazoline-3-carboxamide phosphate Form I.

9. Pharmaceutical composition according to claim 7 wherein compound of formula (II) is *N*-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl} amino)-1-methyl-4,5-dihydro-1*H*-pyrazolo[4,3-*h*]quinazoline-3-carboxamide phosphate Form II.

10. Pharmaceutical compositions according to claims 7 to 9 for use in the treatment of cell proliferative disorders, viral infections, autoimmune and neurodegenerative disorders.

11. Pharmaceutical compositions according to claims 7 to 9 for use in the treatment of carcinoma such as bladder, breast, colon, kidney, liver, lung, including small cell lung cancer, esophagus, gall-bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma; hematopoietic tumors of lymphoid lineage including leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell-lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma and Burkett's lymphoma; hematopoietic tumors of myeloid lineage, including

acute and chronic myelogenous leukemias, myelodysplastic syndrome and promyelocytic leukemia; tumors of mesenchymal origin, including fibrosarcoma and rhabdomyosarcoma; tumors of the central and peripheral nervous system, including astrocytoma neuroblastoma, glioma and schwannomas; other tumors, including melanoma, seminoma, teratocarcinoma, osteosarcoma, xeroderma pigmentosum, keratoxanthoma, thyroid follicular cancer and Kaposi's sarcoma, mesothelioma, highly aneuploid tumors and tumors which do overexpress mitotic checkpoint components like MPS1, MAD2, MAD1, BUB1, BUBR1, BUB3 and others; benign prostate hyperplasia; familial adenomatosis polyposis; neurofibromatosis; psoriasis; vascular smooth cell proliferation associated with atherosclerosis; pulmonary fibrosis; arthritis; glomerulonephritis and post-surgical stenosis and restenosis.

12. Use of a pharmaceutical composition according to claims 7 to 9 in the manufacture of medicaments for use in the treatment of cell proliferative disorders, viral infections, autoimmune and neurodegenerative disorders.

13. Use of a pharmaceutical composition according to claims 7 to 9 in the manufacture of medicaments for use in the treatment of carcinoma such as bladder, breast, colon, kidney, liver, lung, including small cell lung cancer, esophagus, gall-bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma; hematopoietic tumors of lymphoid lineage including leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell-lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma and Burkett's lymphoma; hematopoietic tumors of myeloid lineage, including acute and chronic myelogenous leukemias, myelodysplastic syndrome and promyelocytic leukemia; tumors of mesenchymal origin, including fibrosarcoma and rhabdomyosarcoma; tumors of the central and peripheral nervous system, including astrocytoma neuroblastoma, glioma and schwannomas; other tumors, including melanoma, seminoma, teratocarcinoma, osteosarcoma, xeroderma pigmentosum, keratoxanthoma, thyroid follicular cancer and Kaposi's sarcoma, mesothelioma, highly aneuploid tumors and tumors which do overexpress mitotic checkpoint components like MPS1, MAD2, MAD1, BUB1, BUBR1, BUB3 and others; benign prostate hyperplasia; familial adenomatosis polyposis; neurofibromatosis; psoriasis; vascular smooth cell proliferation associated with

atherosclerosis; pulmonary fibrosis; arthritis; glomerulonephritis and post-surgical stenosis and restenosis.

14. A combination of a compound of formula (II) according to claim 1 with an anti-cancer agent selected from genotoxic agents, mitotic poisons, anti-metabolites, proteasome inhibitors and kinase inhibitors.

15. A combination according to claim 14 wherein compound of formula (II) is *N*-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl} amino)-1-methyl-4,5-dihydro-1*H*-pyrazolo[4,3-*h*]quinazoline-3-carboxamide phosphate Form I.

16. A combination according to claim 14 wherein compound of formula (II) is *N*-(2,6-diethylphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2-methoxyphenyl} amino)-1-methyl-4,5-dihydro-1*H*-pyrazolo[4,3-*h*]quinazoline-3-carboxamide phosphate Form II.

17. A combination according to claims 14 to 16 for use in the treatment of cancers.

18. A combination according to claims 14 to 16 for use in the treatment of carcinoma such as bladder, breast, colon, kidney, liver, lung, including small cell lung cancer, esophagus, gall-bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma; hematopoietic tumors of lymphoid lineage including leukemia, acute lymphocytic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell-lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma and Burkett's lymphoma; hematopoietic tumors of myeloid lineage, including acute and chronic myelogenous leukemias, myelodysplastic syndrome and promyelocytic leukemia; tumors of mesenchymal origin, including fibrosarcoma and rhabdomyosarcoma; tumors of the central and peripheral nervous system, including astrocytoma neuroblastoma, glioma and schwannomas; other tumors, including melanoma, seminoma, teratocarcinoma, osteosarcoma, xeroderma pigmentosum, keratoxanthoma, thyroid follicular cancer and Kaposi's sarcoma, mesothelioma, highly aneuploid tumors and tumors which do overexpress mitotic checkpoint components like MPS1, MAD2, MAD1, BUB1, BUBR1, BUB3 and others; benign prostate hyperplasia; familial adenomatosis polyposis; neurofibromatosis; psoriasis; vascular smooth cell proliferation associated with

atherosclerosis; pulmonary fibrosis; arthritis; glomerulonephritis and post-surgical stenosis and restenosis.

19. Use of a combination according to claims 14 to 16 in the manufacture of medicaments for use in the treatment of cancers.

20. Use of a combination according to claims 14 to 16 in the manufacture of medicaments for use in the treatment of carcinoma such as bladder, breast, colon, kidney, liver, lung, including small cell lung cancer, esophagus, gall-bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma; hematopoietic tumors of lymphoid lineage including leukemia, acute lymphocitic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell-lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma and Burkett's lymphoma; hematopoietic tumors of myeloid lineage, including acute and chronic myelogenous leukemias, myelodysplastic syndrome and promyelocytic leukemia; tumors of mesenchymal origin, including fibrosarcoma and rhabdomyosarcoma; tumors of the central and peripheral nervous system, including astrocytoma neuroblastoma, glioma and schwannomas; other tumors, including melanoma, seminoma, teratocarcinoma, osteosarcoma, xeroderma pigmentosum, keratoxanthoma, thyroid follicular cancer and Kaposi's sarcoma, mesothelioma, highly aneuploid tumors and tumors which do overexpress mitotic checkpoint components like MPS1, MAD2, MAD1, BUB1, BUBR1, BUB3 and others; benign prostate hyperplasia; familial adenomatosis polyposis; neurofibromatosis; psoriasis; vascular smooth cell proliferation associated with atherosclerosis; pulmonary fibrosis; arthritis; glomerulonephritis and post-surgical stenosis and restenosis.